Related references
Note: Only part of the references are listed.Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials
Suhui Qie et al.
ENDOCRINE (2020)
Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients
Priyamvada Singh et al.
DIABETES OBESITY & METABOLISM (2019)
Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment
Reema Mody et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study
Saki Yamamoto et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial
Aika Miya et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
Paolo Pozzilli et al.
DIABETES OBESITY & METABOLISM (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
Julio Rosenstock et al.
DIABETES CARE (2016)
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Zhixia Li et al.
PLOS ONE (2016)
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Julio Rosenstock et al.
DIABETES CARE (2014)
Share Paper
